Detalhe da pesquisa
1.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10236): 1547-1557, 2020 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416780
2.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939400
3.
A genomic code for nucleosome positioning.
Nature
; 442(7104): 772-8, 2006 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-16862119
4.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 26(5): 693-698, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405063
5.
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Eur Urol Oncol
; 2(1): 12-20, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30929841
6.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 27(3): 560, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547461